Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
暂无分享,去创建一个
S. Steinberg | H. Parnes | J. Schlom | J. Wright | R. Madan | W. Dahut | J. Gulley | D. Poole | M. Vergati | K. Tsang | P. Arlen | M. Mohebtash | M. Rauckhorst
[1] I. Lowy,et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[2] Jurgen Müller,et al. BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells , 2012, International journal of cancer.
[3] T. Fojo,et al. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. , 2010, The oncologist.
[4] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[5] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[6] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Steinberg,et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer , 2010, Cancer Immunology, Immunotherapy.
[8] P. Kantoff,et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Schadendorf,et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.
[10] J. Waisman,et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. O’Day,et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] T. Dorff,et al. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC) , 2008 .
[13] S. Steinberg,et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. , 2007, The Journal of urology.
[14] J. Allison,et al. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? , 2007, Novartis Foundation symposium.
[15] J. Schlom,et al. The Human T-Box Mesodermal Transcription Factor Brachyury Is a Candidate Target for T-Cell–Mediated Cancer Immunotherapy , 2007, Clinical Cancer Research.
[16] E. Small,et al. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.
[17] P. Schellhammer,et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Small,et al. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. , 2006, The Journal of urology.
[19] J. Schlom,et al. Multiple Costimulatory Modalities Enhance CTL Avidity , 2005, The Journal of Immunology.
[20] C. N. Coleman,et al. Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer , 2005, Clinical Cancer Research.
[21] J. Schlom,et al. Induction of an Antigen Cascade by Diversified Subcutaneous/Intratumoral Vaccination Is Associated with Antitumor Responses , 2005, Clinical Cancer Research.
[22] S. Groshen,et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[24] Michael S. Kuhns,et al. CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.
[25] D. Parkin,et al. Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.
[26] J. Schlom,et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] H. Griesser,et al. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.
[28] A. Jemal,et al. Global Cancer Statistics , 2011 .
[29] Levine,et al. MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage. , 1999, Molecular urology.